Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. (RLMD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rlmd · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$9.00
+57.3% upside
Low
$8.00
Median: $9 · Last Close: $5.72
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$9.00
57.3% upside
High Target
$10
74.8%
Low Target
$8
39.9%
Current Price
$5.72
as of today
Based on analyst price targets, the RLMD stock price prediction for the next 12 months ranges from $8 to $10. The consensus RLMD price forecast of $9.00 implies 57.3% upside from the current price of $5.72.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.43 | ↓ 5.00% |
1-day model range: $5.39–$5.47. Peak: $5.47 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RLMD · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-20 | Mizuho | Maintains | Outperform→Outperform |
| 2026-01-23 | Leerink Partners | Upgrade ↑ | Market Perform→Outperform |
| 2025-11-19 | Mizuho | Upgrade ↑ | Neutral→Outperform |
| 2024-12-05 | Mizuho | Downgrade ↓ | Outperform→Neutral |
| 2024-12-04 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2024-06-05 | Goldman Sachs | Downgrade ↓ | Neutral→Sell |
| 2023-06-15 | Mizuho | Maintains | Buy→Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-10-14 | Goldman Sachs | Downgrade ↓ | Buy→Neutral |
| 2022-10-14 | Guggenheim | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Relmada Therapeutics, Inc. (RLMD) stock. Of the recent 25 rating actions, 2 were upgrades and 7 were downgrades. 8 analysts currently cover RLMD.
Analyst Recommendation Trends
RLMD analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$10M
↓ 47.4% YoY
Revenue Next Year
$32M
↑ 224.5% YoY
EPS This Year
$-0.80
EPS Next Year
$-0.96
↑ 19.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast RLMD EPS of $-0.80 for the current fiscal year, based on estimates from 2 analysts. The RLMD revenue forecast is $10M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RLMD stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RLMD price target is $9.00 (+57.3% upside), with an analyst consensus of Buy.
The RLMD short-term stock prediction for tomorrow is $5.43 (-5.00%).
Relmada Therapeutics, Inc. trades on NASDAQ under the ticker RLMD. The RLMD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.
Frequently asked questions
RLMD forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month RLMD price target is $9.00, with a high forecast of $10.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +57.3% potential upside from the current price of $5.72.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.